Table 2. Survival analysis of lymphocyte-to-monocyte ratio and clinical factors.
| PFS | OS | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Univariable analysis | Multivariable analysis | Univariable analysis | Multivariable analysis | |||||||
| PFS | P | HR | 95% CI | P | OS (m) | P | HR | 95% CI | P | |
| LMR | 0.003 | 1.14–2.56 | 0.009 | <0.001 | 1.66–3.35 | <0.001 | ||||
| >3.29 | 11.9 | 1 | 33.8 | 1 | ||||||
| ≤3.29 | 8.2 | 1.71 | 13.3 | 2.36 | ||||||
| MBR | <0.001 | 1.25–3.26 | 0.004 | 0.074 | ||||||
| >0.63 | 11.5 | 1 | 22.1 | |||||||
| ≤0.63 | 5.7 | 2.01 | 12.9 | |||||||
| Age | 0.124 | 0.461 | ||||||||
| >65 | 11.5 | 17.8 | ||||||||
| ≤65 | 10.0 | 22.1 | ||||||||
| Sex | 0.631 | 0.254 | ||||||||
| Male | 10.4 | 18.4 | ||||||||
| Female | 11.1 | 23.0 | ||||||||
| DM | 0.061 | 0.925 | ||||||||
| Yes | 10.5 | 21.2 | ||||||||
| No | 10.5 | 23.0 | ||||||||
| Smoking history | 0.484 | 0.255 | ||||||||
| Non-smoker | 11.1 | 22.5 | ||||||||
| Smoker | 9.5 | 21.3 | ||||||||
| EGFR Mutation a | 0.001 | 1.06–3.45 | 0.032 | 0.286 | ||||||
| Common | 11.3 | 1 | 21.4 | |||||||
| Uncommon | 4.9 | 1.91 | 13.4 | |||||||
| Distant metastasis | <0.001 | 1.01–2.86 | 0.044 | <0.001 | 1.41–3.27 | <0.001 | ||||
| 0–2 | 11.5 | 1 | 23.0 | 1 | ||||||
| >2 | 6.5 | 1.70 | 10.5 | 2.15 | ||||||
| Malignant effusion | 0.007 | 0.75–1.63 | 0.599 | 0.010 | 0.98–1.97 | 0.065 | ||||
| Yes | 9.2 | 1.11 | 17.5 | 1.39 | ||||||
| No | 11.5 | 1 | 23.0 | 1 | ||||||
| PS | <0.001 | 0.97–2.37 | 0.071 | <0.001 | 1.98–5.87 | <0.001 | ||||
| ECOG 0–1 | 11.5 | 1 | 24.5 | 1 | ||||||
| ECOG 2–4 | 5.0 | 1.51 | 8.4 | 3.41 | ||||||
a Exon 19 deletion and L858R mutations were defined as common mutations. Other mutations or compound mutations were defined as uncommon mutations.
PFS, progression-free survival; OS, overall survival; LMR, lymphocyte-to-monocyte ratio; MBR, 1-month-to-baseline ratio of LMR; DM, diabetes mellitus; EGFR, epidermal growth factor receptor; PS, performance status; ECOG, Eastern Cooperative Oncology Group